1. Home
  2. CINGW vs CADL Comparison

CINGW vs CADL Comparison

Compare CINGW & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • CADL
  • Stock Information
  • Founded
  • CINGW N/A
  • CADL 1999
  • Country
  • CINGW United States
  • CADL United States
  • Employees
  • CINGW 13
  • CADL N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • CADL Biotechnology: Pharmaceutical Preparations
  • Sector
  • CINGW Health Care
  • CADL Health Care
  • Exchange
  • CINGW Nasdaq
  • CADL Nasdaq
  • Market Cap
  • CINGW N/A
  • CADL N/A
  • IPO Year
  • CINGW 2021
  • CADL 2021
  • Fundamental
  • Price
  • CINGW $0.05
  • CADL $4.51
  • Analyst Decision
  • CINGW
  • CADL Strong Buy
  • Analyst Count
  • CINGW 0
  • CADL 1
  • Target Price
  • CINGW N/A
  • CADL $11.00
  • AVG Volume (30 Days)
  • CINGW N/A
  • CADL 530.3K
  • Earning Date
  • CINGW N/A
  • CADL 11-14-2024
  • Dividend Yield
  • CINGW N/A
  • CADL N/A
  • EPS Growth
  • CINGW N/A
  • CADL N/A
  • EPS
  • CINGW N/A
  • CADL N/A
  • Revenue
  • CINGW N/A
  • CADL N/A
  • Revenue This Year
  • CINGW N/A
  • CADL N/A
  • Revenue Next Year
  • CINGW N/A
  • CADL N/A
  • P/E Ratio
  • CINGW N/A
  • CADL N/A
  • Revenue Growth
  • CINGW N/A
  • CADL N/A
  • 52 Week Low
  • CINGW N/A
  • CADL $0.77
  • 52 Week High
  • CINGW N/A
  • CADL $14.30
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • CADL 43.42
  • Support Level
  • CINGW N/A
  • CADL $4.45
  • Resistance Level
  • CINGW N/A
  • CADL $5.57
  • Average True Range (ATR)
  • CINGW 0.00
  • CADL 0.47
  • MACD
  • CINGW 0.00
  • CADL 0.09
  • Stochastic Oscillator
  • CINGW 0.00
  • CADL 40.62

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: